From: Increased serum sTRAIL levels were correlated with survival in bevacizumab-treated metastatic colon cancer
Healthy Controls
(n = 10)
Colon Ca patients
(n = 16)
Age
51, 8
55, 18
Sex
Male
8 (%80)
12(%75)
Female
2(%20)
4(%25)